Carmell Therapeutics increased its IP portfolio with the issuance of Canada Patent No. 2,701,187, addressing Methods and Apparatus for Manufacturing Plasma Based Plastics.
The company is launching a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care. PBM uses pooled plasma to create products which accelerate the healing of bone and soft tissues.
Sources: Carmell Therapeutics Corp.; ORTHOWORLD Inc.